You are here

Article Text

Article menu
Download PDFPDF
Correspondence
Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect
  1. Vincent Germain1,2,
  2. Marc Scherlinger1,2,3,
  3. Thomas Barnetche1,
  4. Thierry Schaeverbeke1,2
  5. On behalf of the Fédération Hospitalo-universitaire ACRONIM
  1. 1 Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux, Service de Rhumatologie, Bordeaux, France
  2. 2 Department of Rheumatology, Université de Bordeaux, Bordeaux, France
  3. 3 Department of Rheumatology, CNRS-UMR 5164 Immuno ConcEpT, Bordeaux, France
  1. Correspondence to Professor Thierry Schaeverbeke, Service de rhumatologie, Hôpital Pellegrin, Bordeaux 33076, France; thierry.schaeverbeke{at}chu-bordeaux.fr

http://dx.doi.org/10.1136/annrheumdis-2018-214374

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    To date, all available data regarding the switch from bio-originator to its biosimilar are reassuring, and the switch has been recommended as a shared patient–physician decision in recent consensus-based recommendations.1 In particular, the Norway's infliximab switching study (NOR-SWITCH study), a 52-week randomised double-blind trial, strongly supports the efficacy and safety of the switch from originator infliximab (OI) to its biosimilar CT-P13 in patients with a stable disease.2 However, long-term follow-up data are required to confirm the efficacy and safety of the switch.

    In a previous real-life study, we demonstrated a high acceptance of 89% (89/100) and a 72% (64/89) retention rate after a median follow-up of 33 weeks in a cohort of patients with stable rheumatic diseases switched from OI to CT-P13.3 This retention rate was lower compared with two control cohorts: a historic cohort of 82 patients treated with OI in 2013, and …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • VG and MS contributed equally.

    • Contributors VG and MS collected the data and wrote the manuscript. MS and TB analysed the data. TS designed the study and helped in data analysis. All authors critically reviewed the paper and validated the last version of it.

    • Competing interests TS received honoraria as consultant from: Amgen, AbbVie, BMS, Janssen, MSD, Novartis, Pfizer, Roche Chugaï, UCB. TS received a research grant from Pfizer (unrelated to this work). The other authors report no conflicts of interests.

    • Patient consent Not required.

    • Provenance and peer review Not commissioned; externally peer reviewed.